HEADER HYDROLASE/HYDROLASE INHIBITOR 18-DEC-02 1NH0 TITLE 1.03 A STRUCTURE OF HIV-1 PROTEASE: INHIBITOR BINDING INSIDE AND TITLE 2 OUTSIDE THE ACTIVE SITE COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE RETROPEPSIN; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: HIV-1 PROTEASE; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: PEPTIDOMIMETIC INHIBITOR KI2-PHE-GLU-GLU-NH2; COMPND 9 CHAIN: I, J; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 7 MOL_ID: 2; SOURCE 8 SYNTHETIC: YES KEYWDS ASPARTYL PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS, INHIBITOR DESIGN, KEYWDS 2 HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.BRYNDA,P.REZACOVA,M.FABRY,M.HOREJSI,M.HRADILEK,M.SOUCEK, AUTHOR 2 J.KONVALINKA,J.SEDLACEK REVDAT 4 16-AUG-23 1NH0 1 REMARK LINK REVDAT 3 13-JUL-11 1NH0 1 VERSN REVDAT 2 24-FEB-09 1NH0 1 VERSN REVDAT 1 13-APR-04 1NH0 0 JRNL AUTH J.BRYNDA,P.REZACOVA,M.FABRY,M.HOREJSI,R.STOURACOVA, JRNL AUTH 2 J.SEDLACEK,M.SOUCEK,M.HRADILEK,M.LEPSIK,J.KONVALINKA JRNL TITL A PHENYLNORSTATINE INHIBITOR BINDING TO HIV-1 PROTEASE: JRNL TITL 2 GEOMETRY, PROTONATION, AND SUBSITE-POCKET INTERACTIONS JRNL TITL 3 ANALYZED AT ATOMIC RESOLUTION JRNL REF J.MED.CHEM. V. 47 2030 2004 JRNL REFN ISSN 0022-2623 JRNL PMID 15056001 JRNL DOI 10.1021/JM031105Q REMARK 2 REMARK 2 RESOLUTION. 1.03 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.03 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 6.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.131 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.130 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.165 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 2.500 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 2205 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 88225 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.122 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.122 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.157 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 2.500 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 1909 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 76731 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1616 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 15 REMARK 3 SOLVENT ATOMS : 233 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1839.6 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1670.0 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 20 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 16567 REMARK 3 NUMBER OF RESTRAINTS : 20084 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.016 REMARK 3 ANGLE DISTANCES (A) : 0.036 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.030 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.144 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.175 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.054 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.010 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.054 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.085 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REMARK 3 ANISOTROPIC SCALING APPLIED BY THE METHOD OF PARKIN, MOEZZI & HOPE, REMARK 3 J.APPL.CRYST. 28 (1995) 53-56 REMARK 4 REMARK 4 1NH0 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-DEC-02. REMARK 100 THE DEPOSITION ID IS D_1000017861. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-NOV-01 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 2 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9930 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XDS, XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 88784 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.030 REMARK 200 RESOLUTION RANGE LOW (A) : 54.100 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 9.800 REMARK 200 R MERGE (I) : 0.08900 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 10.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.03 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.06 REMARK 200 COMPLETENESS FOR SHELL (%) : 93.3 REMARK 200 DATA REDUNDANCY IN SHELL : 5.20 REMARK 200 R MERGE FOR SHELL (I) : 0.59500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.850 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: EPMR REMARK 200 STARTING MODEL: 1VIK REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 36.64 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.94 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 14.45650 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 46.57350 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 33.28100 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 46.57350 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 14.45650 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 33.28100 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, I, J REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 REMARK 400 THE PEPTIDOMIMETIC INHIBITOR KI2-PHE-GLU-GLU-NH2 IS PEPTIDE-LIKE, A REMARK 400 MEMBER OF INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: PEPTIDOMIMETIC INHIBITOR KI2-PHE-GLU-GLU-NH2 REMARK 400 CHAIN: I, J REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 41 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 8 NE - CZ - NH1 ANGL. DEV. = 4.9 DEGREES REMARK 500 GLY A 17 C - N - CA ANGL. DEV. = -14.9 DEGREES REMARK 500 CYS A 95 CA - CB - SG ANGL. DEV. = 23.9 DEGREES REMARK 500 GLN B 2 CG - CD - NE2 ANGL. DEV. = 24.5 DEGREES REMARK 500 GLY B 16 O - C - N ANGL. DEV. = -12.3 DEGREES REMARK 500 GLY B 17 C - N - CA ANGL. DEV. = 15.7 DEGREES REMARK 500 ASP B 30 CB - CG - OD2 ANGL. DEV. = 7.0 DEGREES REMARK 500 ARG B 41 NE - CZ - NH2 ANGL. DEV. = 3.0 DEGREES REMARK 500 ILE B 64 N - CA - CB ANGL. DEV. = 14.2 DEGREES REMARK 500 CYS B 95 CA - CB - SG ANGL. DEV. = 15.4 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO B 79 48.33 -81.88 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 BME B 5002 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 6001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 6002 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE BME A 5001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE BME B 5002 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN I OF PEPTIDOMIMETIC REMARK 800 INHIBITOR KI2-PHE-GLU-GLU-NH2 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN J OF PEPTIDOMIMETIC REMARK 800 INHIBITOR KI2-PHE-GLU-GLU-NH2 DBREF 1NH0 A 1 99 UNP P03367 POL_HV1BR 69 167 DBREF 1NH0 B 1 99 UNP P03367 POL_HV1BR 69 167 DBREF 1NH0 I 1 5 PDB 1NH0 1NH0 1 5 DBREF 1NH0 J 1 5 PDB 1NH0 1NH0 1 5 SEQRES 1 A 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE LEU ILE GLU SEQRES 6 A 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE LEU ILE GLU SEQRES 6 B 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 I 5 KI2 PHE GLU GLU NH2 SEQRES 1 J 5 KI2 PHE GLU GLU NH2 HET KI2 I 1 33 HET NH2 I 5 1 HET KI2 J 1 23 HET NH2 J 5 1 HET SO4 A6001 5 HET BME A5001 4 HET SO4 B6002 5 HET BME B5002 1 HETNAM KI2 3-BENZYLOXYCARBONYLAMINO-2-HYDROXY-4-PHENYL-BUTYRIC HETNAM 2 KI2 ACID HETNAM NH2 AMINO GROUP HETNAM SO4 SULFATE ION HETNAM BME BETA-MERCAPTOETHANOL FORMUL 3 KI2 2(C18 H19 N O5) FORMUL 3 NH2 2(H2 N) FORMUL 5 SO4 2(O4 S 2-) FORMUL 6 BME 2(C2 H6 O S) FORMUL 9 HOH *233(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLN A 92 GLY A 94 5 3 HELIX 3 3 GLY B 86 THR B 91 1 6 HELIX 4 4 GLN B 92 GLY B 94 5 3 SHEET 1 1 3 THR B 96 ASN B 98 0 SHEET 2 1 3 THR A 96 ASN A 98 -1 N THR A 96 O ASN B 98 SHEET 3 1 3 GLN B 2 THR B 4 -1 N ILE B 3 O LEU A 97 SHEET 1 5 7 GLY A 52 ILE A 66 0 SHEET 2 5 7 LEU A 10 ILE A 15 -1 O LYS A 14 N GLU A 65 SHEET 3 5 7 GLN A 18 LEU A 24 -1 O GLN A 18 N ILE A 15 SHEET 4 5 7 ILE A 84 ILE A 85 1 N ILE A 85 O LEU A 23 SHEET 5 5 7 VAL A 32 LEU A 33 -1 O VAL A 32 N ILE A 84 SHEET 6 5 7 HIS A 69 VAL A 77 1 O LEU A 76 N LEU A 33 SHEET 7 5 7 GLY A 52 ILE A 66 -1 N ARG A 57 O VAL A 77 SHEET 1 14 7 GLY B 52 ILE B 66 0 SHEET 2 14 7 LEU B 10 ILE B 15 -1 O LYS B 14 N GLU B 65 SHEET 3 14 7 GLN B 18 LEU B 24 -1 O GLN B 18 N ILE B 15 SHEET 4 14 7 ILE B 84 ILE B 85 1 N ILE B 85 O LEU B 23 SHEET 5 14 7 VAL B 32 LEU B 33 -1 O VAL B 32 N ILE B 84 SHEET 6 14 7 HIS B 69 VAL B 77 1 O LEU B 76 N LEU B 33 SHEET 7 14 7 GLY B 52 ILE B 66 -1 N ARG B 57 O VAL B 77 LINK SG ACYS A 67 S2 ABME A5001 1555 1555 2.00 LINK C KI2 I 1 N PHE I 2 1555 1555 1.32 LINK C GLU I 4 N NH2 I 5 1555 1555 1.30 LINK C KI2 J 1 N PHE J 2 1555 1555 1.33 LINK C GLU J 4 N NH2 J 5 1555 1555 1.24 SITE 1 AC1 5 TRP A 42 PRO A 44 ARG A 57 HOH A6087 SITE 2 AC1 5 GLU B 34 SITE 1 AC2 6 HOH A6014 GLN B 2 ARG B 41 ASN B 98 SITE 2 AC2 6 HOH B6070 HOH B6106 SITE 1 AC3 4 VAL A 11 THR A 12 CYS A 67 GLN B 7 SITE 1 AC4 3 THR B 12 CYS B 67 HOH B6105 SITE 1 AC5 30 ASP A 25 GLY A 27 ALA A 28 ASP A 29 SITE 2 AC5 30 ASP A 30 ILE A 47 GLY A 48 GLY A 49 SITE 3 AC5 30 ILE A 50 VAL A 82 ILE A 84 HOH A6010 SITE 4 AC5 30 HOH A6015 ARG B 8 LEU B 23 ASP B 25 SITE 5 AC5 30 GLY B 27 ALA B 28 ASP B 30 VAL B 32 SITE 6 AC5 30 ILE B 47 GLY B 48 GLY B 49 ILE B 50 SITE 7 AC5 30 VAL B 82 ILE B 84 HOH I 6 HOH I 7 SITE 8 AC5 30 HOH I 8 HOH I 10 SITE 1 AC6 29 THR A 4 TRP A 6 PRO A 39 GLY A 40 SITE 2 AC6 29 ARG A 41 HOH A6064 LYS B 14 PRO B 44 SITE 3 AC6 29 LYS B 45 LYS B 55 VAL B 56 ARG B 57 SITE 4 AC6 29 CYS B 67 GLY B 68 GLN B 92 ILE B 93 SITE 5 AC6 29 GLY B 94 HOH B6030 HOH B6034 HOH B6052 SITE 6 AC6 29 HOH B6079 HOH B6085 HOH B6115 HOH J 8 SITE 7 AC6 29 HOH J 22 HOH J 93 HOH J 152 HOH J 177 SITE 8 AC6 29 HOH J 225 CRYST1 28.913 66.562 93.147 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.034587 0.000000 0.000000 0.00000 SCALE2 0.000000 0.015024 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010736 0.00000